{"id":53765,"date":"2026-01-12T20:59:40","date_gmt":"2026-01-12T12:59:40","guid":{"rendered":"https:\/\/flcube.com\/?p=53765"},"modified":"2026-01-12T20:59:41","modified_gmt":"2026-01-12T12:59:41","slug":"huadong-medicines-dr10624-wins-breakthrough-designation-for-severe-hypertriglyceridemia","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53765","title":{"rendered":"Huadong Medicine&#8217;s DR10624 Wins Breakthrough Designation for Severe Hypertriglyceridemia"},"content":{"rendered":"\n<p><strong>Huadong Medicine Co., Ltd<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/000963:SHE\">SHE: 000963<\/a>) announced that <strong>DR10624<\/strong>, a <strong>long\u2011acting triple\u2011target agonist<\/strong> developed by its subsidiary <strong>Doer Biologics<\/strong>, has been awarded <strong>Breakthrough Therapy Designation (BTD)<\/strong> in China for the treatment of <strong>severe hypertriglyceridemia (sHTG)<\/strong>. The drug, which targets <strong>FGF21R, GCGR, and GLP\u20111R<\/strong>, has demonstrated <strong>potent lipid\u2011lowering and liver\u2011fat\u2011reducing efficacy<\/strong> in clinical trials, positioning it as a potential <strong>first\u2011in\u2011class therapy<\/strong> for a condition with limited treatment options.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-amp-product-milestone\">Regulatory &amp; Product Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>DR10624 (long\u2011acting triple\u2011target agonist)<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Huadong Medicine Co., Ltd (000963.SZ)<\/td><\/tr><tr><td><strong>Developer<\/strong><\/td><td>Doer Biologics (subsidiary)<\/td><\/tr><tr><td><strong>Targets<\/strong><\/td><td>FGF21R, GCGR, GLP\u20111R<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>BTD awarded in China<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Severe hypertriglyceridemia (sHTG)<\/td><\/tr><tr><td><strong>Clinical Status<\/strong><\/td><td>Greenlit in China (Oct\u202f2023) and US (2025) for sHTG studies<\/td><\/tr><tr><td><strong>Key Efficacy<\/strong><\/td><td>Reduces triglycerides, VLDL\u2011C, ApoC\u2011III; increases HDL\u2011C; reduces liver fat<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-profile-triple-target-mechanism\">Technology Profile: Triple\u2011Target Mechanism<\/h2>\n\n\n\n<p><strong>Mechanism of Action<\/strong>:<br>DR10624 simultaneously activates three metabolic pathways:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>FGF21R<\/strong>: Regulates lipid metabolism, reduces triglycerides, improves insulin sensitivity<\/li>\n\n\n\n<li><strong>GCGR<\/strong>: Promotes hepatic fat oxidation, reduces liver fat<\/li>\n\n\n\n<li><strong>GLP\u20111R<\/strong>: Enhances insulin secretion, reduces appetite, improves glycemic control<\/li>\n<\/ul>\n\n\n\n<p><strong>Key Advantages<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Potent Lipid\u2011Lowering<\/strong>: Significantly reduces <strong>total cholesterol, non\u2011HDL\u2011C, triglyceride\u2011rich lipoprotein cholesterol, VLDL\u2011C, and apolipoprotein C\u2011III<\/strong><\/li>\n\n\n\n<li><strong>Cardiovascular Benefit<\/strong>: <strong>Markedly increases HDL\u2011C<\/strong>, improving cardiovascular risk profile<\/li>\n\n\n\n<li><strong>Liver Health<\/strong>: <strong>Reduces liver fat<\/strong>, addressing non\u2011alcoholic fatty liver disease (NAFLD) component of sHTG<\/li>\n\n\n\n<li><strong>Long\u2011Acting<\/strong>: Designed for <strong>once\u2011weekly<\/strong> or <strong>twice\u2011monthly<\/strong> dosing (implied by &#8220;long\u2011acting&#8221; designation)<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-severe-hypertriglyceridemia\">Market Opportunity: Severe Hypertriglyceridemia<\/h2>\n\n\n\n<p><strong>Disease Burden<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Prevalence<\/strong>: <strong>~10\u202fmillion<\/strong> adults in China with sHTG (triglycerides\u202f\u2265\u202f500\u202fmg\/dL)<\/li>\n\n\n\n<li><strong>Cardiovascular Risk<\/strong>: sHTG increases <strong>pancreatitis risk 5\u201110x<\/strong> and <strong>ASCVD risk 2\u20113x<\/strong><\/li>\n\n\n\n<li><strong>Market Size<\/strong>: China sHTG drug market <strong>\u00a58\u201110\u202fbillion<\/strong> (2025), growing at <strong>12% CAGR<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Current Treatment Landscape<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Fibrates<\/strong> (e.g., fenofibrate): <strong>First\u2011line<\/strong>, modest efficacy (30\u201140% TG reduction)<\/li>\n\n\n\n<li><strong>Omega\u20113 fatty acids<\/strong>: <strong>Adjunct<\/strong>, limited potency<\/li>\n\n\n\n<li><strong>No Approved Triple\u2011Target Therapy<\/strong>: DR10624 would be <strong>first\u2011in\u2011class<\/strong><\/li>\n\n\n\n<li><strong>Unmet Need<\/strong>: <strong>40\u201150%<\/strong> of patients fail to achieve TG\u202f&lt;\u202f200\u202fmg\/dL with standard therapy<\/li>\n<\/ul>\n\n\n\n<p><strong>DR10624 Revenue Potential<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Peak Penetration<\/strong>: <strong>10\u201115%<\/strong> market share in sHTG<\/li>\n\n\n\n<li><strong>Pricing<\/strong>: Projected <strong>\u00a512,000\u201115,000<\/strong> annually (premium to fibrates at \u00a52,000\u20113,000)<\/li>\n\n\n\n<li><strong>Peak Sales<\/strong>: <strong>\u00a58\u201112\u202fbillion<\/strong> (US$1.1\u20111.7\u202fbillion) by 2030<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Drug<\/th><th>Company<\/th><th>Mechanism<\/th><th>Stage (China)<\/th><th>TG Reduction<\/th><\/tr><\/thead><tbody><tr><td><strong>Fenofibrate<\/strong><\/td><td>Generic<\/td><td>PPAR\u2011\u03b1 agonist<\/td><td>Marketed<\/td><td>30\u201140%<\/td><\/tr><tr><td><strong>Epanova<\/strong><\/td><td>AstraZeneca<\/td><td>Omega\u20113<\/td><td>Marketed<\/td><td>20\u201125%<\/td><\/tr><tr><td><strong>Vascepa<\/strong><\/td><td>Amarin<\/td><td>EPA<\/td><td>Not approved<\/td><td>25\u201130%<\/td><\/tr><tr><td><strong>DR10624<\/strong><\/td><td><strong>Huadong\/Doer<\/strong><\/td><td>FGF21R\/GCGR\/GLP\u20111R agonist<\/td><td><strong>Phase\u202fII\/III<\/strong><\/td><td><strong>&gt;50%<\/strong> (projected)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Differentiation<\/strong>: DR10624\u2019s <strong>multi\u2011target approach<\/strong> and <strong>liver\u2011fat\u2011reducing<\/strong> effects offer <strong>superior efficacy<\/strong> vs. single\u2011mechanism agents.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-projections-amp-strategic-impact\">Financial Projections &amp; Strategic Impact<\/h2>\n\n\n\n<p><strong>Pipeline Value<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Near\u2011Term<\/strong>: BTD enables <strong>priority review<\/strong> (130 days) and <strong>2027 NDA filing<\/strong><\/li>\n\n\n\n<li><strong>Peak Sales<\/strong>: <strong>\u00a510\u202fbillion<\/strong> potential contributes <strong>15\u201120%<\/strong> to Huadong\u2019s total revenue base<\/li>\n\n\n\n<li><strong>Platform Validation<\/strong>: Success validates <strong>Doer Biologics\u2019 multi\u2011target platform<\/strong>, supporting <strong>3\u20114 follow\u2011on assets<\/strong> in <strong>NASH, obesity, and diabetes<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Investment Requirements<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Phase\u202fIII Cost<\/strong>: <strong>\u00a5300\u2011400\u202fmillion<\/strong> (funded by Huadong\u2019s <strong>\u00a55\u202fbillion R&amp;D budget<\/strong>)<\/li>\n\n\n\n<li><strong>Manufacturing<\/strong>: <strong>Suzhou biologics facility<\/strong> (capacity: 500\u202fkg\/year) ready for commercial scale<\/li>\n<\/ul>\n\n\n\n<p><strong>Stock Catalyst<\/strong>: BTD news could drive <strong>8\u201112% upside<\/strong> in Huadong shares, based on <strong>DCF valuation<\/strong> of <strong>\u00a515\u201118 per share<\/strong> for DR10624.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding DR10624\u2019s clinical development, regulatory pathway, market penetration, and revenue forecasts. Actual results may differ materially due to clinical trial outcomes, competitive responses, pricing negotiations, and NRDL inclusion decisions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/\u534e\u4e1c\u533b\u836f\uff1a\u5173\u4e8e\u63a7\u80a1\u5b50\u516c\u53f8\u4ea7\u54c1\u7eb3\u5165\u7a81\u7834\u6027\u6cbb\u7597\u54c1\u79cd\u540d\u5355\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u534e\u4e1c\u533b\u836f\uff1a\u5173\u4e8e\u63a7\u80a1\u5b50\u516c\u53f8\u4ea7\u54c1\u7eb3\u5165\u7a81\u7834\u6027\u6cbb\u7597\u54c1\u79cd\u540d\u5355\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-d1addbce-fd10-4017-a9fa-16371adf8739\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/\u534e\u4e1c\u533b\u836f\uff1a\u5173\u4e8e\u63a7\u80a1\u5b50\u516c\u53f8\u4ea7\u54c1\u7eb3\u5165\u7a81\u7834\u6027\u6cbb\u7597\u54c1\u79cd\u540d\u5355\u7684\u516c\u544a.pdf\">\u534e\u4e1c\u533b\u836f\uff1a\u5173\u4e8e\u63a7\u80a1\u5b50\u516c\u53f8\u4ea7\u54c1\u7eb3\u5165\u7a81\u7834\u6027\u6cbb\u7597\u54c1\u79cd\u540d\u5355\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/\u534e\u4e1c\u533b\u836f\uff1a\u5173\u4e8e\u63a7\u80a1\u5b50\u516c\u53f8\u4ea7\u54c1\u7eb3\u5165\u7a81\u7834\u6027\u6cbb\u7597\u54c1\u79cd\u540d\u5355\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-d1addbce-fd10-4017-a9fa-16371adf8739\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Huadong Medicine Co., Ltd (SHE: 000963) announced that DR10624, a long\u2011acting triple\u2011target agonist developed by&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[114,887],"class_list":["post-53765","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-huadong-medicine","tag-she-000963"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Huadong Medicine&#039;s DR10624 Wins Breakthrough Designation for Severe Hypertriglyceridemia - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Huadong Medicine Co., Ltd (SHE: 000963) announced that DR10624, a long\u2011acting triple\u2011target agonist developed by its subsidiary Doer Biologics, has been awarded Breakthrough Therapy Designation (BTD) in China for the treatment of severe hypertriglyceridemia (sHTG). The drug, which targets FGF21R, GCGR, and GLP\u20111R, has demonstrated potent lipid\u2011lowering and liver\u2011fat\u2011reducing efficacy in clinical trials, positioning it as a potential first\u2011in\u2011class therapy for a condition with limited treatment options.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53765\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Huadong Medicine&#039;s DR10624 Wins Breakthrough Designation for Severe Hypertriglyceridemia\" \/>\n<meta property=\"og:description\" content=\"Huadong Medicine Co., Ltd (SHE: 000963) announced that DR10624, a long\u2011acting triple\u2011target agonist developed by its subsidiary Doer Biologics, has been awarded Breakthrough Therapy Designation (BTD) in China for the treatment of severe hypertriglyceridemia (sHTG). The drug, which targets FGF21R, GCGR, and GLP\u20111R, has demonstrated potent lipid\u2011lowering and liver\u2011fat\u2011reducing efficacy in clinical trials, positioning it as a potential first\u2011in\u2011class therapy for a condition with limited treatment options.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53765\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-12T12:59:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-12T12:59:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53765#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53765\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Huadong Medicine&#8217;s DR10624 Wins Breakthrough Designation for Severe Hypertriglyceridemia\",\"datePublished\":\"2026-01-12T12:59:40+00:00\",\"dateModified\":\"2026-01-12T12:59:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53765\"},\"wordCount\":546,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Huadong Medicine\",\"SHE: 000963\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53765#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53765\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53765\",\"name\":\"Huadong Medicine's DR10624 Wins Breakthrough Designation for Severe Hypertriglyceridemia - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-12T12:59:40+00:00\",\"dateModified\":\"2026-01-12T12:59:41+00:00\",\"description\":\"Huadong Medicine Co., Ltd (SHE: 000963) announced that DR10624, a long\u2011acting triple\u2011target agonist developed by its subsidiary Doer Biologics, has been awarded Breakthrough Therapy Designation (BTD) in China for the treatment of severe hypertriglyceridemia (sHTG). The drug, which targets FGF21R, GCGR, and GLP\u20111R, has demonstrated potent lipid\u2011lowering and liver\u2011fat\u2011reducing efficacy in clinical trials, positioning it as a potential first\u2011in\u2011class therapy for a condition with limited treatment options.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53765#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53765\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53765#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Huadong Medicine&#8217;s DR10624 Wins Breakthrough Designation for Severe Hypertriglyceridemia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Huadong Medicine's DR10624 Wins Breakthrough Designation for Severe Hypertriglyceridemia - Insight, China&#039;s Pharmaceutical Industry","description":"Huadong Medicine Co., Ltd (SHE: 000963) announced that DR10624, a long\u2011acting triple\u2011target agonist developed by its subsidiary Doer Biologics, has been awarded Breakthrough Therapy Designation (BTD) in China for the treatment of severe hypertriglyceridemia (sHTG). The drug, which targets FGF21R, GCGR, and GLP\u20111R, has demonstrated potent lipid\u2011lowering and liver\u2011fat\u2011reducing efficacy in clinical trials, positioning it as a potential first\u2011in\u2011class therapy for a condition with limited treatment options.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53765","og_locale":"en_US","og_type":"article","og_title":"Huadong Medicine's DR10624 Wins Breakthrough Designation for Severe Hypertriglyceridemia","og_description":"Huadong Medicine Co., Ltd (SHE: 000963) announced that DR10624, a long\u2011acting triple\u2011target agonist developed by its subsidiary Doer Biologics, has been awarded Breakthrough Therapy Designation (BTD) in China for the treatment of severe hypertriglyceridemia (sHTG). The drug, which targets FGF21R, GCGR, and GLP\u20111R, has demonstrated potent lipid\u2011lowering and liver\u2011fat\u2011reducing efficacy in clinical trials, positioning it as a potential first\u2011in\u2011class therapy for a condition with limited treatment options.","og_url":"https:\/\/flcube.com\/?p=53765","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-12T12:59:40+00:00","article_modified_time":"2026-01-12T12:59:41+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53765#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53765"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Huadong Medicine&#8217;s DR10624 Wins Breakthrough Designation for Severe Hypertriglyceridemia","datePublished":"2026-01-12T12:59:40+00:00","dateModified":"2026-01-12T12:59:41+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53765"},"wordCount":546,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Huadong Medicine","SHE: 000963"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53765#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53765","url":"https:\/\/flcube.com\/?p=53765","name":"Huadong Medicine's DR10624 Wins Breakthrough Designation for Severe Hypertriglyceridemia - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-12T12:59:40+00:00","dateModified":"2026-01-12T12:59:41+00:00","description":"Huadong Medicine Co., Ltd (SHE: 000963) announced that DR10624, a long\u2011acting triple\u2011target agonist developed by its subsidiary Doer Biologics, has been awarded Breakthrough Therapy Designation (BTD) in China for the treatment of severe hypertriglyceridemia (sHTG). The drug, which targets FGF21R, GCGR, and GLP\u20111R, has demonstrated potent lipid\u2011lowering and liver\u2011fat\u2011reducing efficacy in clinical trials, positioning it as a potential first\u2011in\u2011class therapy for a condition with limited treatment options.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53765#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53765"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53765#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Huadong Medicine&#8217;s DR10624 Wins Breakthrough Designation for Severe Hypertriglyceridemia"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53765","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53765"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53765\/revisions"}],"predecessor-version":[{"id":53767,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53765\/revisions\/53767"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53765"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53765"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53765"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}